Dr. Aragon-Ching is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
8081 Innovation Park Dr
Level 5 - Great Falls Clinic
Fairfax, VA 22031Phone+1 571-472-1180Fax+1 571-472-1197
Summary
- Jeanny Aragon-Ching, MD, FACP, FASCO, is a renowned oncologist based in Fairfax, VA, specializing in genitourinary oncology. She currently serves as the Clinical Program Director of Genitourinary Oncology at Inova Schar Cancer Institute and the Medical Director of Clinical Research. Holds academic appointment as Associate Professor of Medical Education, University of Virginia. She completed her residency and chief residency in Internal Medicine at the Albert Einstein Healthcare Network, then pursued a fellowship in Hematology and Medical Oncology at the National Institutes of Health Clinical Center. Dr. Aragon-Ching currently serves as a GU Medical Oncologist at Inova Fairfax Hospital, adding on to her previous experience as an Assistant Professor at George Washington University Medical Center then promoted to Associate Professor at George Washington University Medical Center. She has contributed numerous publications and has been involved in a range of clinical trials, particularly in the areas of prostate and bladder cancer. Recognized for her expertise, she received numerous honors, including being named a Top Doctor by Northern Virginia Magazine, Washingtonian, and International Association of Oncologists, and voted America's Best Prostate Cancer Oncologists 2024, as well as participated in the ASCO Leadership Development Program and chaired and presented in various meetings.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2004 - 2008
Albert Einstein Healthcare NetworkChief Residency, Internal Medicine, 2003 - 2004- Albert Einstein Healthcare NetworkResidency, Internal Medicine, 2000 - 2003
University of Santo TomasClass of 1997
University of Santo TomasBS, Physical Therapy, Cum Laude, 1988 - 1993
Certifications & Licensure
VA State Medical License 2015 - 2026
DC State Medical License 2008 - 2018
MD State Medical License 2004 - 2018
PA State Medical License 2001 - 2004
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- America's Best Prostate Cancer Oncologists 2024 Newsweek, 2024
- Named Top Doctor Northern Virginia Magazine, 2017, 2019-2021
- Named Top Doctor Washingtonian, 2018
- Join now to see all
Clinical Trials
- S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 08
- A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors Start of enrollment: 2015 Jan 01
- A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer Start of enrollment: 2015 Jul 13
- Join now to see all
Publications & Presentations
PubMed
- Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS.Neal D Shore, Christian Gratzke, Susan Feyerabend, Patrick Werbrouck, Joan Carles
The Oncologist. 2024-07-05 - Biochemically recurrent prostate cancer in the era of EMBARK and PSMA PET imaging: everything has changed, except the patients.David J Einstein, Jeanny B Aragon-Ching, Fatima Karzai, Ravi A Madan
Current Opinion in Oncology. 2024-05-01 - Refining the subgroup analyses and optimal patient population in the JAVELIN Bladder 100 trial.Jeanny B Aragon-Ching
Translational Andrology and Urology. 2024-04-30
Journal Articles
- Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial CarcinomaCora N Sternberg, Jeanny B Aragon-Ching, Daniel P Petrylak, Petros Grivas, The New England Journal of Medicine
- The Emerging Role of Combination Angiogenesis Inhibitors and Immune Checkpoint Inhibitors in the Treatment of Metastatic Renal Cell CancerNizam A, Logan R, Gupta B, Aragon-Ching, JB, Kidney Cancer, 8/7/2019
Lectures
- Metastatic RCC trials: Balancing efficacy and quality-of-lifeEAU Annual Congress 2021 - 7/9/2021
- Current Approaches to Urothelial and Variant Cancers: Tumor Board PresentationASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019
- ABCs of ADTHotel Monaco, Washington, DC; National Alliance of State Prostate Cancer Coalition - 10/19/2019
- Join now to see all
Other
- Key Abstracts GU Cancers ASCO 2024Neeraj Agrawal and JeannyAragon-Ching
https://dailynews.ascopubs.org/do/podcast-key-abstracts-gu-cancers-asco24
5/25/2024 - First-Line Treatment of Cisplatin-Ineligible Patients With Metastatic Urothelial Carcinoma: The Pursuit of Improved OutcomesAragon-Ching JB, Grivas P., ASCO Daily News
https://dailynews.ascopubs.org/do/first-line-treatment-cisplatin-ineligible-patients-metastatic-urothelial-carcinoma
1/17/2023 - Advances in Genitourinary Cancers at ASCO22Neeraj Agrawal and Jeanny Aragon-Ching, ASCO Daily News
https://dailynews.ascopubs.org/do/10.1200/ADN.22.0618/full/
6/18/2022 - Join now to see all
Authored Content
- How We Treat Metastatic Renal Cell Carcinoma: Options Beyond First-Line TherapyJanuary 2023
- Controversies Surrounding the Use of Novel Antiandrogens in Nonmetastatic Castrate-Resistant Prostate CancerNovember 2019
- Perspective on Targeted radiation therapy yields high response rates in metastatic prostate cancerFebruary 2019
- The Evolving Treatment Landscape for Nonmetastatic Castration-Resistant Prostate CancerJanuary 2019
- Contemporary systemic therapy for advanced urothelial carcinoma11/1/2018
- Prostate, Bladder & Non-urothelial cancers, RCC and Germ Tumor Questions9/21/2017
- Join now to see all
Press Mentions
Three GU25 Studies Report on the Association Between Gut Microbiome Composition and Genitourinary CancersFebruary 13th, 2025
Radiotherapy-Based Approach Offers Lower Risk of Distant Metastases to Surgery in High-Risk Prostate CancerFebruary 14th, 2025
2025 FASCO Recipients Part – 1 The American Society of Clinical Oncology (ASCO) recently released the FASCO recipients for 2025.February 11th, 2025- Join now to see all
Committees
- Track Chair Urothelial Carcinoma, ASCO GU Cancers Symposium Committee 2019 2018 - Present
- Member, Bladder; Track co-chair, Renal, ASCO GU Cancers Symposium Committee 2017 - 2018
- Member, ASCO Cancer Education Committe 2016 - 2018
- Member, Prostate; Track Chair - Renal, ASCO GU Cancers Committee 2016 - 2017
Professional Memberships
- Fellow
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
